RAPGEF3 and atherosclerosis: In macrophages, cAMP significantly upregulates the expression of the ox-LDL receptor LOX-1 by activating its downstream effector molecule EPAC1 (rather than PKA), thereby promoting the uptake and intracellular accumulation of oxidized LDL, ultimately leading to the formation of foam cells and the development of atherosclerosis [157].